Riskpilot← Back to searchSign inGet full accessEUSA Pharma (Denmark) ApS
APSIn liquidationCVR 39055988Rygårds Allé 104Activities of advertising agencies · NACE 7311Est. 20171 employees
Revenue 2023
DKK 1,9M
-37% vs 2022
EBITDA margin
5.5%
-59% vs 2022
Equity ratio
80.7%
Financial strength
Net profit 2023
DKK 141K
-29% vs 2022
| Revenue | DKK 1,9M | -37% |
| EBITDA | DKK 106K | -59% |
| Net profit | DKK 141K | -29% |
| Total assets | DKK 2M | +1% |
| Equity | DKK 1,6M | +9% |
| Employees | 1 | — |
Legal name
EUSA Pharma (Denmark) ApS
CVR number
39055988
Legal form
Anpartsselskab
NACE code
7311 · Activities of advertising agencies
Founded
2. november 2017
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Rygårds Allé 104
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 2.059 | 9.829 | 9.429 | 3.038 | 1.929 |
| Staff expenses | -1.774 | -8.946 | -8.782 | -2.779 | -1.823 |
| EBITDA | 285 | 883 | 647 | 259 | 106 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 285 | 883 | 647 | 259 | 106 |
| Net financials | -9 | -104 | -26 | -33 | 75 |
| Profit before tax | 277 | 779 | 622 | 226 | 181 |
| Tax | 48 | 172 | 139 | 27 | 40 |
| Net profit | 228 | 607 | 483 | 198 | 141 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 889 | 2.956 | 1.733 | 2.014 | 2.039 |
| Equity | 215 | 823 | 1.305 | 1.504 | 1.645 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 674 | 2.134 | 428 | 510 | 394 |
| Total debt | 674 | 2.134 | 428 | 510 | 394 |
EBITDA margin
5.5%
This company
15.8%
Market median
-65% vs market
20192023
Equity ratio
80.7%
This company
38.2%
Market median
+111% vs market
20192023
Return on equity
8.6%
This company
18.4%
Market median
-53% vs market
20192023
Net profit margin
7.3%
This company
8.1%
Market median
-10% vs market
20192023
Asset turnover
0.95×
This company
1.12×
Market median
+15% vs market
20192023
Debt / equity
0.24×
This company
0.62×
Market median
+61% vs market
20192023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Former (9) | ||
EJ Management | Management | 2017 – 2022 |
EP Founder | Founder | 2017 – 2024 |
JK Management | Management | 2022 – 2024 |
NJ Unofficial title | Unofficial title | 2024 – 2024 |
FP Management | Management | 2022 – 2024 |
FC Management | Management | 2021 – 2022 |
DK Management | Management | 2017 – 2022 |
LL Management | Management | 2022 – 2024 |
LS Management | Management | 2017 – 2021 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EUSA Pharma (Denmark) ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Jane Johnson | Management | 0 companies |
| EUSA Pharma, UK, Ltd. | Founder | 0 companies |
| Joakim Karl Viktor Åberg | Management | 0 companies |
| Nicolai Jung | Unofficial title | 0 companies |
| Francesco Palombi | Management | 0 companies |
| Frank Carsten Thiel | Management | 0 companies |
| Dev Kumar | Management | 0 companies |
| Luigi Longinotti | Management | 0 companies |
| Lee Scot Morley | Management | 0 companies |